NasdaqCM - Delayed Quote USD

iCAD, Inc. (ICAD)

3.6800
-0.0800
(-2.13%)
At close: June 13 at 4:00:02 PM EDT
3.6100
-0.07
(-1.90%)
After hours: June 13 at 7:46:23 PM EDT
Loading Chart for ICAD
  • Previous Close 3.7600
  • Open 3.7000
  • Bid 3.6500 x 100
  • Ask 3.7100 x 100
  • Day's Range 3.6750 - 3.7700
  • 52 Week Range 1.1800 - 4.0100
  • Volume 154,697
  • Avg. Volume 815,633
  • Market Cap (intraday) 100.317M
  • Beta (5Y Monthly) 1.39
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1900
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.75

iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for?breast?cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solutions to identifying pathologies and pinpointing prevalent cancers earlier; and a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging, and computed tomography. In addition, the company suite offers solutions for cancer detection, density assessment, and personalized risk evaluation based on a 2D or 3D mammogram's collection of images. Additionally, its density assessment standardizes and simplifies breast density reporting by algorithmically examining a woman's breast anatomy from the mammogram image. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

www.icadmed.com

66

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ICAD

View More

Performance Overview: ICAD

Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICAD
101.09%
S&P 500 (^GSPC)
1.62%

1-Year Return

ICAD
137.42%
S&P 500 (^GSPC)
10.00%

3-Year Return

ICAD
8.91%
S&P 500 (^GSPC)
59.40%

5-Year Return

ICAD
66.45%
S&P 500 (^GSPC)
96.53%

Compare To: ICAD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ICAD

View More

Valuation Measures

Annual
As of 6/13/2025
  • Market Cap

    100.32M

  • Enterprise Value

    80.59M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.98

  • Price/Book (mrq)

    3.26

  • Enterprise Value/Revenue

    4.13

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -26.77%

  • Return on Assets (ttm)

    -9.03%

  • Return on Equity (ttm)

    -16.53%

  • Revenue (ttm)

    19.53M

  • Net Income Avi to Common (ttm)

    -5.23M

  • Diluted EPS (ttm)

    -0.1900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.03M

  • Total Debt/Equity (mrq)

    1.00%

  • Levered Free Cash Flow (ttm)

    -90k

Research Analysis: ICAD

View More

Company Insights: ICAD

Research Reports: ICAD

View More

People Also Watch